New First-Line Treatment Approved for NSCLC with an EGFR Mutation
September 28, 2018
Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based on a randomized trial that showed a significant improvement in progression-free survival for patients who received VIZIMPRO compared to the standard-of-care treatment. VIZIMPRO, an EGFR inhibitor targeted therapy, is an oral drug that is taken once a day.The following treatments are approved for first-line treatment of NSCLC with an EGFR mutation: GILOTRIF (afatinib), IRESSA (gefitinib), TAGRISSO (osimertinib), TARCEVA (erlotinib), VIZIMPRO (dacomitinib).Click here to read the full press release.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.